LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

LLY

1,076.31

+0.13%↑

JNJ

207.79

+1.08%↑

ABBV

230.14

+0.15%↑

UNH

327.75

+0.78%↑

AZN

92.5

+0.34%↑

Accueil・Liste d'Actions・Cogent Biosciences Inc

Cogent Biosciences Inc

Fermé

39.63 0.08

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

39.54

Max

40.16

Chiffres clés
By Trading Economics
Revenu	-7.4M -81M
BPA	-0.5
Marge bénéficiaire	-1,582.642
Employés	205
EBITDA	-6.8M -79M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+17.55% upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	3.9B 6B
Ouverture précédente	39.55
Clôture précédente	39.63

Score Technique

By Trading Central

Confiance

Bearish Evidence

4.88 / 5.87 Support & Résistance

Cogent Biosciences Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 déc. 2025, 21:41 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

24 déc. 2025, 14:57 UTC

Acquisitions, Fusions, Rachats

Accenture to Acquire Cabel Industry from Fibonacci Group

25 déc. 2025, 23:42 UTC

Market Talk

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 déc. 2025, 23:40 UTC

Market Talk

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 déc. 2025, 00:20 UTC

Acquisitions, Fusions, Rachats

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 déc. 2025, 22:22 UTC

Acquisitions, Fusions, Rachats

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 déc. 2025, 21:26 UTC

Acquisitions, Fusions, Rachats

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 déc. 2025, 19:35 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 déc. 2025, 19:35 UTC

Market Talk

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 déc. 2025, 19:09 UTC

Market Talk

Acquisitions, Fusions, Rachats

Global Equities Roundup: Market Talk

24 déc. 2025, 19:09 UTC

Market Talk

Acquisitions, Fusions, Rachats

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 déc. 2025, 19:06 UTC

Market Talk

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

24 déc. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Futures Give Back Some Gains -- Market Talk

24 déc. 2025, 17:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

24 déc. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 déc. 2025, 17:08 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 déc. 2025, 16:53 UTC

Acquisitions, Fusions, Rachats

Nike Climb Boosts Dow, S&P 500 -- WSJ

24 déc. 2025, 16:31 UTC

Market Talk

Acquisitions, Fusions, Rachats

ServiceNow Gets Top-Tier Asset and Talent With Armis Buy -- Market Talk

24 déc. 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

Lam Research Is at All-Time Highs. Its CEO Just Sold $27 Million Worth of Stock. -- Barrons.com

24 déc. 2025, 16:17 UTC

Market Talk

Dollar Stable as U.S. Layoffs Remain at Bay -- Market Talk

24 déc. 2025, 15:33 UTC

Acquisitions, Fusions, Rachats

Nike Shares Get a Lift After Apple's Tim Cook Doubles His Personal Stake -- WSJ

24 déc. 2025, 15:30 UTC

Acquisitions, Fusions, Rachats

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 déc. 2025, 15:19 UTC

Acquisitions, Fusions, Rachats

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 déc. 2025, 14:49 UTC

Acquisitions, Fusions, Rachats

Mexico's Ollamani Sells Stake in Azteca Stadium

24 déc. 2025, 14:19 UTC

Market Talk

U.S. Natural Gas Futures Move Lower After Big Jump -- Market Talk

24 déc. 2025, 14:08 UTC

Acquisitions, Fusions, Rachats

Apple CEO Tim Cook Buys $3 Million of Nike Shares. The Stock Is Rising. -- Barrons.com

24 déc. 2025, 14:06 UTC

Market Talk

Oil Futures Edge Up on Geopolitical Risk Premium -- Market Talk

24 déc. 2025, 13:24 UTC

Market Talk

Canada's Economy Needs More Help Amid Dismal GDP Report -- Market Talk

24 déc. 2025, 12:59 UTC

Acquisitions, Fusions, Rachats

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion. -- Barrons.com

24 déc. 2025, 12:51 UTC

Acquisitions, Fusions, Rachats

Disney Could Be the Real Winner from the Warner Takeover Battle. Here's Why. -- Barrons.com

Comparaison

Variation de prix

Cogent Biosciences Inc prévision

Objectif de Prix

By TipRanks

17.55% hausse

Prévisions sur 12 Mois

Moyen 47.22 USD 17.55%

Haut 67 USD

Bas 34 USD

Basé sur 10 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

10 ratings

Achat

Maintien

Vente

Basé sur 10 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

4.88 / 5.87Support & Résistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.